Array
(
    [results] => Array
        (
            [0] => Array
                (
                    [ArticleID] => 564068
                    [Title] => Elderly colorectal cancer patients live cancer-free longer
                    [Summary] => 
The results of the international phase III study NO16968 (XELOXA), an open-label, randomized trial of Xelox (oral capecitabine in combination with intravenous oxaliplatin) versus 5-fluorouracil/leucovorin (5-FU/LV) as adjuvant therapy for patients with stage III colon cancer who have undergone surgery, showed the superiority of Xelox versus 5-FU/LV in terms of disease-free survival (DFS).
                    [DatePublished] => 2010-04-08 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

            [1] => Array
                (
                    [ArticleID] => 561678
                    [Title] => Gene variant, GERD together raise esophageal Ca risk: Specific genetic markers were found
                    [Summary] => 
Patients with gastroesophageal reflux disease who also have a specific epidermal growth factor gene polymorphism appear to have a significantly increased risk for esophageal adenocarcinoma, a case-control study suggests.
                    [DatePublished] => 2010-03-28 00:00:00
                    [ColumnID] => 136231
                    [Focus] => 0
                    [AuthorID] => 1805110
                    [AuthorName] => Charles C. Chante MD
                    [SectionName] => Opinion
                    [SectionUrl] => opinion
                    [URL] => 
                )

        )

)

GASTROINTESTINAL CANCERS SYMPOSIUM

Array
(
    [results] => Array
        (
            [0] => Array
                (
                    [ArticleID] => 564068
                    [Title] => Elderly colorectal cancer patients live cancer-free longer
                    [Summary] => 
The results of the international phase III study NO16968 (XELOXA), an open-label, randomized trial of Xelox (oral capecitabine in combination with intravenous oxaliplatin) versus 5-fluorouracil/leucovorin (5-FU/LV) as adjuvant therapy for patients with stage III colon cancer who have undergone surgery, showed the superiority of Xelox versus 5-FU/LV in terms of disease-free survival (DFS).
                    [DatePublished] => 2010-04-08 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

            [1] => Array
                (
                    [ArticleID] => 561678
                    [Title] => Gene variant, GERD together raise esophageal Ca risk: Specific genetic markers were found
                    [Summary] => 
Patients with gastroesophageal reflux disease who also have a specific epidermal growth factor gene polymorphism appear to have a significantly increased risk for esophageal adenocarcinoma, a case-control study suggests.
                    [DatePublished] => 2010-03-28 00:00:00
                    [ColumnID] => 136231
                    [Focus] => 0
                    [AuthorID] => 1805110
                    [AuthorName] => Charles C. Chante MD
                    [SectionName] => Opinion
                    [SectionUrl] => opinion
                    [URL] => 
                )

        )

)

abtest

Elderly colorectal cancer patients live cancer-free longer

April 8, 2010 - 12:00am

The results of the international phase III study NO16968 (XELOXA), an open-label, randomized trial of Xelox (oral capecitabine in combination with intravenous oxaliplatin) versus 5-fluorouracil/leucovorin (5-FU/LV)...

Science and Environment

Gene variant, GERD together raise esophageal Ca risk: Specific genetic markers were found

By YOUR DOSE OF MEDICINE | By Charles C. Chante MD | March 28, 2010 - 12:00am

Patients with gastroesophageal reflux disease who also have a specific epidermal growth factor gene polymorphism appear to have a significantly increased risk for esophageal adenocarcinoma, a case-control study...

Opinion